Twitter: @edd1819, Instagram: @bluestar0910, Facebook: SDN — Science, Digital & Current Affairs
By EDD K. USMAN
(SDN) — SCIENTISTS across the world are in crucial race to develop an effective vaccine, or cure, for the coronavirus disease (Covid-19).
None yet of the scientific racers has come close to the research finish line.
The novel coronavirus is now ravaging countries after countries since December 2019. A vaccine is still far-off.
At least Russia had given an August 2020 time line to register its vaccine, as reported on May 16 this year by Tass.com.
At that time the vaccine’s development was in the stage of pre-clinical trials.
“I believe by the end of summer [a vaccine will be registered]. “I would say so. In August, I hope that everything will go as planned and there will be no surprises,” said Alexander Gunzburg, director of the Gamaleya National Research Center for Epidemiology and Microbiology (GNRCEM).
Pre-clinical trials involve determining the vaccine’s toxicity, reactogenicity, and other criteria. The results will show if it’s a go to test the vaccine on humans, the Tass report said.
Amid this cloud of uncertainties in the scientific and pharmaceutical world, and among governments, the United States’ Johns Hopkins University (JHU) on its global Covid-19 Dashboard showed 13.32 million confirmed cases with more than half a million fatalities. The total number of cases as July 15 include 7,399,310 recovered patients.
Here’s the latest report on the vaccine from the Russian news agency Tass that’s live online a few hours ago.
It said the vaccine was tested at the Burdenko Main Military Clinical Hospital and showed it’s “safe and well tolerated” according to the Russian Ministry of Defense (MOD).
“The available data based on laboratory and instrumental research makes it possible to say the vaccine is safe and well tolerated,” the MOF said.
A total of 18 volunteers were involved in the trials of the vaccine whose vital signs showed they were inside normal limits for 28 days after administering the Covid-19 vaccine.
The Defense Ministry further sais there were “No adverse events, complaints about health, complications or side effects were recorded.”
On the hand, the ministry said the volunteers will have to return to the hospital on the 42nd day after their vaccination for the final medical examination and diagnostics.
The volunteers for the trials that started in June included two groups, military servicemen and civilians. In military group there were 50 people with five women and 10 medical workers.
In another report on July 8 by Tass, it said Russia is presently developing 17 potential vaccine to cure Covid-19.
“There are 17 vaccines that ha e shown to be promising, and in-depth work on their development is currently underway,” said Russian Health Minister Mikhail Murashko.
Meanwhile, from sciencealert.com, Moderna, an American biotechnology company, said today (Tuesday) its Covid-19 vaccine has shown early promise, and it will go into its final stage of human trials “after promising early results were published in an influential journal.”
Russia did not share as of yet the data from its vaccine trials.
Moderna will recruit 30,000 participants in the United States for the Phase 3 trial. It will go on until October 27.
The Phase 3 trial was designed “to show whether the vaccine is safe and can prevent infection by the SARS-CoV-2 virus, or — if people still get infected — whether it can prevent the infection progressing toward symptoms.”
“If they do get symptoms, the vaccine can still be considered a success if it stops severe cases of Covid-19.”
Moderna’s vaccine had shown to generate immune responses in the Phase 1 trial. (SDN)
Featured image of coronavirus by href=”https://www.pexels.com/photo/concept-of-covid-19-in-red-background-4031867/” rel=”nofollow”>Pexels.com</a>
Sources: Tass.com and Sciencealert.com.